# Beta Glucan Stress Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/beta-glucan-stress-randomized-trial-evidence-review
Category: evidence-review
Summary: Beta Glucan Stress Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mix
Last reviewed: 2026-08-04
Reviewed by: Migaku Evidence Review
# Beta Glucan Stress Randomized Trial: What the Evidence Says

## Quick Answer

Beta Glucan Stress Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation | preclinical study | 4 | 2026-06-02 | 10.3390/nu18111794 |
| Low-dose of yeast beta-glucan on respiratory symptoms and psychological well-being in moderately stressed adults | preclinical study | 4 | 2026-03-20 | 10.1016/j.isci.2026.115120 |

## What The Sources Report

- By interacting with innate pattern recognition receptors (PRRs), including Dectin-1 and Toll-like receptors (TLRs), expressed on gut-associated lymphoid tissue (GALT) and immune cells, β-1,3-glucans regulate both innate and adaptive immune responses. [Samiksha Fnu (2026); evidence level 4]
- Table 2 A summary of β-glucans derived from different fungal sources and their associated therapeutic properties is provided in. [Samiksha Fnu (2026); evidence level 4]
- However, most clinical trials to date have focused on moderate to high doses of YBG (≥250 mg/day) over short to moderate durations (ranging from 7 days to 3 months).Evidence on the efficacy, tolerability, and sustainability of low-dose supplementation remains scarce, despite its practical advantages for daily, long-term use. [Habibullah Nur Nadia Mohamad (2026); evidence level 4]
- The modest declines across all groups suggest a trend toward improved vitality but no differential treatment effect. [Habibullah Nur Nadia Mohamad (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For beta glucan stress randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Samiksha Fnu (2026). Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation. DOI: 10.3390/nu18111794. PMCID: PMC13258535. PMID: 42280437. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258535/
- Habibullah Nur Nadia Mohamad (2026). Low-dose of yeast beta-glucan on respiratory symptoms and psychological well-being in moderately stressed adults. DOI: 10.1016/j.isci.2026.115120. PMCID: PMC13010125. PMID: 41883579. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13010125/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.